Aller au contenuAller au menuAller à la recherche

Michael Wiener"The Alzheimers Disease neuroimaging initiative identifying and treating Alzheimers at an early stage"

Abstract :

Until recently, there has been comparatively little interest in using MRI for the study of neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia and Lewy body disease, Parkinson’s disease, amyotropic lateral sclerosi, and other degenerative diseases of the brain. There are several reasons for this:

1) The lack of interest on the part of the MRI community was reflective of the relative lack of interest on the part of the medical community at large.

2) The lack of interest was due to the fact that no treatments were available for neurodegenerative disease; thus, fostering the attitude “if you can’t treat it, why diagnose it?”

3) For the most part, neurodegenerative diseases are not characterized by lesions, although various types of lesions, especially in white matter, often occur in these conditions.

4) Neurodegenerative diseases do produce brain atrophy due to loss of neuronal cell bodies and axons until the disease is very advanced and the atrophy becomes extreme.

Improved information concerning the pathogenesis of Alzheimer’s disease now raises the possibility that treatments that modify the rate of neurodegeneration will be available for human testing and clinical trials. Validated biomarkers, which have increased statistical power when compared to clinical/cognitive tests, are needed to detect response to treatments. Thus, in order to assess and compare possible biomarkers, the National Institute of Aging and the pharmaceutical industry, funded the Alzheimer’s Disease Neuroimaging Initiative (ADNI), have set the following goals:

1) Develop improved methods, which will lead to uniform standards for acquiring longitudinal multisite MRI, PET, blood, and CSF biomarker data in patients with Alzheimer's disease and mild cognitive impairment versus elderly controls.

2) Create a generally accessible data repository, which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical, cognitive, and biomarker data for validation of imaging surrogates.
3) Determine those methods that provide maximum power to distinguish treatment effects in trials involving Alzheimer's disease and mild cognitive impairment patients. Michael Weiner, MD
© from The San Francisco Medical Society

Selected publications

Chao, L.L., Meyerhoff, D.J., Cardenas-Nicolson, V.A., Rothlind, J.C., and Weiner, M.W.: Abnormal CNV in Chronic Heavy Drinkers. Clinical Neurophysiology
Boxer, A., Kramer, J.H., Schuff, N., Du, A.T., Weiner, M.W.: Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment. Nuerology,
Schuff, N., Zhu, X., Du, A., Jahng, G.H., Soher, B., Maudsley, A., Weiner M.W.: Magnetic Resonance Spectroscopic Imaging Reconstruction with Deformable Shape-Intensity Models. Magnetic Resonance in Medicine

Scientific focus :

L'ADNI est une étude dont l'objectif est d'identifier les marqueurs prédictifs d'Alzheimer. Il s'agit de déterminer des méthodes standardisées d'imagerie et d'analyse biologique en suivant de manière prospective 200 patients atteints de la maladie d'Alzheimer, 400 personnes avec un déclin cognitif léger . Les données sont ouvertes à la communauté des chercheur.

Jean Marc Orgogozo